MEDFORD, Mass.–(BUSINESS WIRE)–Torus Biosystems (“Torus” or the “Company”), the company pioneering molecular in vitro diagnostics for point of care use, today announced the appointment of Nancy Hill as lead Independent Director to the Company’s Board of Directors. Ms. Hill will also serve as a member of the Board’s Audit Committee.
“Nancy’s experience in developing, commercializing, and scaling the distribution of innovative technologies to improve health outcomes aligns well with our mission, making her an ideal addition to the Torus Board of Directors,” said Shawn Marcell, President and CEO of Torus. “Her expertise and deep operating experience will be instrumental at such an important time for the Company, and we are confident that her guidance will help us deliver on our research, development, and commercialization milestones.”
“I am excited about contributing to the progress of this innovative company. Torus has the opportunity to deliver comprehensive, personalized, infectious disease diagnostics at the point of care in a truly revolutionary way,” said Nancy Hill.
Ms. Hill has more than 30 years of experience in diagnostics, biotech, and device organizations. She currently serves as Chief Product Officer at AltPep, a biotech start-up developing disease-modifying treatment and detection tools for amyloid diseases, including Alzheimer’s and Parkinson’s diseases. Previously, she was Executive Vice President of Operations and Program Management and an officer at Adaptive Biotechnologies. She was a member of the core executive team that grew the company from early start-up through IPO and beyond. Prior to Adaptive, Ms. Hill led Sales and Marketing and was a member of the executive team at Spiration, Inc., a venture-backed medical device company that was acquired by Olympus. She has also held senior leadership positions in Berlex Laboratories, Immunex Corporation and Amgen. Ms. Hill holds a Bachelor’s degree from the University of Washington and an M.B.A. from the Kellogg School of Management at Northwestern University (Kellogg). She is currently President of the Seattle Chapter of the Healthcare Businesswomen’s Association (HBA), and a member of Kellogg’s Alumni Council and Hawryluk Scholars Mentorship Council. Ms. Hill is a recipient of HBA’s Leadership Excellence and Dedication Award.
About Torus Biosystems
Torus Biosystems, a spinout from the Harvard Wyss Institute for Biologically Inspired Engineering, is on a mission to transform patient lives by delivering breakthrough innovations in infectious disease diagnostics. The Company is currently developing syndromic testing solutions based on the integration of novel technologies, including qPCR and microarray technologies, that enable rapid, quantitative, and highly multiplexed detection of microbial pathogens and resistance genes that ultimately lead to improved patient outcomes. Learn more about how Torus can help clinicians deliver better patient care, combat antibiotic resistance, and promote antimicrobial stewardship by visiting the website at www.torus.bio and connecting on social media @Twitter and @LinkedIn.